Preprocedural high - sensitivity C-reactive protein (hsCRP) decrease during intensive atorvastatin therapy: the presumable impact on atherosclerosis progression after coronary stenting


Cite item

Full Text

Abstract

Proinflammatory status is the risk factor for coronary atherosclerosis progression after coronary stenting (CS). Intensive statin treatment is associated with hsCRP concentration decline. Aim: to evaluate prognostic significance of preprocedural hsCRP level reduction with intensive statin regimen for coronary atherosclerosis progression during one year after CS. Materials and methods. We enrolled 102 patients with stable angina who were on list for scheduled CS. Group I (n=37) patients received atorvastatin 80 mg for 7 days before and 3 months after CS with further dose adjustment according to LDL; group II (n=65) patients received atorvastatin 20-40 mg/day for LDL goal achievement. HsCRP level was assessed at baseline, before CS and after 1, 3, 6 and 12 months. Coronary atherosclerosis progression was defined as new ≥50% stenosis or ≥30% increase of ≥20% pre - existing stenosis according to coronary angiography (CA) 1 year after CS. Results. Baseline concentration of hsCRP was comparable: 0.21 (0.13; 0.38) vs. 0.20 (0.1; 0.44) mg/dl in groups I and II, respectively (p>0.05). In group I significant hsCRP level decrease to 0.14 (0.07; 0.32) mg/dl (p<0.05) was determined after 7 days. Coronary atherosclerosis progression was revealed in 10 (41%) patients in group I and in 20 (47%) in group II according to CA. HsCRP level ≥0.26 was associated with coronary atherosclerosis progression during 12 months (OR 4.2 for total study group, 95% CI 1.4-12.3; p=0.01). Conclusion. Elevated preprocedural hsCRP level is associated with coronary atherosclerosis progression after CS. Intensive atorvastatin regimen for one week before CS leads to preprocedural hsCRP level reduction.

About the authors

A M Shchinova

National Medical Research Center of Cardiology

Email: alexsasha_shi@inbox.ru
лаборант-исследователь лаб. клеточной иммунологии НИИЭК; ORCID: 0000-0002-3631-5026 Moscow, Russia

G V Shlevkova

National Medical Research Center of Cardiology

аспирант отд. легочной гипертензии и заболеваний сердца НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia

A Yu Filatova

National Medical Research Center of Cardiology

лаборант-исследователь лаб. клеточной иммунологии НИИЭК Moscow, Russia

A V Potekhina

National Medical Research Center of Cardiology

к.м.н., м.н.с. отд. легочной гипертензии и заболеваний сердца НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia

A K Osokina

National Medical Research Center of Cardiology

аспирант отд. легочной гипертензии и заболеваний сердца НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia

I V Romasov

National Medical Research Center of Cardiology

аспирант отд. рентгенэндоваскулярных методов диагностики и лечения НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia

E A Zharova

National Medical Research Center of Cardiology

д.м.н., проф., зав. отд-нием легочной гипертензии и заболеваний сердца НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia

E A Noeva

National Medical Research Center of Cardiology

к.м.н., с.н.с. отд. легочной гипертензии и заболеваний сердца НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia

A N Samko

National Medical Research Center of Cardiology

д.м.н., проф., руководитель отд. рентгенэндоваскулярных методов диагностики и лечения НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia

V P Masenko

National Medical Research Center of Cardiology

д.м.н., проф., руководитель лаб. нейрогуморальной регуляции сердечно-сосудистых заболеваний Moscow, Russia

T I Arefieva

National Medical Research Center of Cardiology

д.б.н., руководитель лаб. клеточной иммунологии НИИЭК Moscow, Russia

S I Provatorov

National Medical Research Center of Cardiology

д.м.н., в.н.с. отд. легочной гипертензии и заболеваний сердца НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia

References

  1. Гребенщикова И.А. Эпидемиология ишемической болезни сердца и значение показателей периферического атеросклероза и функционального состояния почек в развитии коронарной болезни сердца у мужчин. Современные проблемы науки и образования. 2011;(5).
  2. Williams T.N, Zhang C.X, Game B.A, He L, Huang Y. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal - regulated kinase pathway:: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol. 2004;24:61-6. doi: 10.1161/01.ATV.0000104014.24367.16
  3. Wågsäter D, Zhu C, Björkegren J, Skogsberg J, Eriksson P. MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr(-/-)Apob(100/100) mouse. Int J Mol Med. 2011;28:247-53. doi: 10.3892/ijmm.2011.693
  4. Dabek J, Glogowska-Ligus J, Szadorska B. Transcription activity of MMP-2 and MMP-9 metalloproteinase genes and their tissue inhibitor (TIMP-2) in acute coronary syndrome patients. J Postgrad Med. 2013;59:115-20. doi: 10.4103/0022-3859.113836
  5. Guo C, et al. Correlation between the severity of coronary artery lesions and levels of estrogen, hs-CRP and MMP-9. Exp Ther Med. 2014;7:1177-80. doi: 10.3892/etm.2014.1565
  6. Szalai A.J, Agrawal A, Greenhough T.J, Volanakis, J.E. C-reactive protein: structural biology, gene expression, and host defense function. Immunol Res. 1997;16:127-36. doi: 10.1007/BF02786357
  7. Szmitko P.E, Verma S. C-reactive protein and statins: IL-8 as a molecular link? Clin Sci Lond Engl. 2005;108:493-5. doi: 10.1042/CS20050093
  8. Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol. 2005;25:2216-21. doi: 10.1161/01.ATV.0000183718.62409.ea
  9. Devaraj S, Xu D.Y, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003;107:398-404. doi: 10.1161/01.cir. 0000052617.91920.fd
  10. Mirjanic-Azaric B, et al. Atorvastatin in stable angina patients lowers CCL2 and ICAM1 expression: pleiotropic evidence from plasma mRNA analyses. Clin Biochem. 2013;46:1526-31. doi: 10.1016/j.clinbiochem.2013.06.006
  11. Ferri C, et al. C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis. Curr Pharm Des. 2007;13:1631-45. doi: 10.2174/138161207780831301
  12. Libby P, Ridker P.M. Novel inflammatory markers of coronary risk: theory versus practice. Circulation. 1999;100:1148-50. doi: 10.1161/01.cir.100.11.1148
  13. Ridker P.M, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-8. doi: 10.1056/NEJMoa042378
  14. Takemoto M, Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-9. doi: 10.1161/hq1101.098486
  15. Mausner-Fainberg K, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T-cells. Atherosclerosis. 2008;197:829-39. doi: 10.1016/j.atherosclerosis.2007.07.031
  16. Nissen S.E, et al. Effect of intensive compared with moderate lipid - lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-80. doi: 10.1001/jama.291.9.1071
  17. Albert M.A, Danielson E, Rifai N, Ridker P.M. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70. doi: 10.1001/jama.286.1.64
  18. Kim J-S, et al. Efficacy of high - dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv. 2010;3:332-9. doi: 10.1016/j.jcin.2009.11.021
  19. Isaacsohn J.L, et al. Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol. 2000;86:250-2. doi: 10.1016/s0002-9149(00)00872-9
  20. La Rosa J.C, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35. doi: 10.1056/NEJMoa050461
  21. Рекомендации по лечению стабильной ишемической болезни сердца ESC. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines
  22. Kinlay S, et al. High - dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560-6. doi: 10.1161/01.CIR.0000091404.09558.AF
  23. Loppnow H, et al. Statins potently reduce the cytokine - mediated IL-6 release in SMC/MNC cocultures. J Cell Mol Med. 2011;15:994-1004. doi: 10.1111/j.1582-4934.2010.01036.x
  24. Miyazaki Y, et al. Effect of statins on atherogenic serum amyloid A and α1-antitrypsin low - density lipoprotein complexes. Int J Cardiol. 2016;225:332-6. doi: 10.1016/j.ijcard.2016.09.116
  25. Ridker P.M. High - sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813-8. doi: 10.1161/01.cir. 103.13.1813
  26. Park D-W, et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug - eluting stent implantation. Circulation. 2009;120:1987-95. doi: 10.1161/CIRCULATIONAHA.109.876763
  27. Delhaye C, et al. Long - term prognostic value of preprocedural C-reactive protein after drug - eluting stent implantation. Am J Cardiol. 2010;105:826-32. doi: 10.1016/j.amjcard.2009.10.064
  28. Iijima R, et al. Pre - procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. Heart Br Card Soc. 2009;95:107-12. doi: 10.1136/hrt.2008.153635
  29. Park D-W, et al. Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug - eluting stent implantation. Heart Br Card Soc. 2007;93:1087-92. doi: 10.1136/hrt.2006.099762
  30. Ridker P.M, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet Lond Engl. 2017. doi: 10.1016/S0140-6736(17)32814-3.
  31. Mor A, Luboshits G, Planer D, Keren G, George J. Altered status of CD4(+)CD25(+) regulatory T-cells in patients with acute coronary syndromes. Eur Heart J. 2006;27:2530-7. doi: 10.1093/eurheartj/ehl222
  32. Kim Y.C, Kim K.K, Shevach E.M. Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor - beta signal transduction. Immunology. 2010;130:484-93. doi: 10.1111/j.1365-2567.2010.03269.x
  33. Meng X, et al. Statins induce the accumulation of regulatory T-cells in atherosclerotic plaque. Mol Med Camb Mass. 2012;18:598-605. doi: 10.2119/molmed.2011.00471
  34. Filatova A.Yu, Kuznetsova G.V, Shchinova A.M, Osokina A.K, Potekhina A.V, et al. Influence of short - term intensive atorvastatin therapy on lymphocyte and monocyte subpopulations and CCR2, CCR5, CX3CR1 and TLR4 expression in blood of patients with stable angina. 85th EAS Congress, Prague, 2016.
  35. Nabatov A.A, Pollakis G, Linnemann T, Paxton W.A, de Baar M.P. Statins disrupt CCR5 and RANTES expression levels in CD4(+) T-lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. PloS One. 2007;(2):e470. doi: 10.1371/journal.pone.0000470
  36. Veillard N.R, et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis. 2006;188:51-8. doi: 10.1016/j.atherosclerosis.2005.10.015
  37. Martínez-González J, Alfón J, Berrozpe M, Badimon L. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis. 2001;159:27-33. doi: 10.1016/S0021-9150(01)00469-5

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies